This study was conducted to measure quality of life of patients with end stage renal disease on different modalities of treatment. A total of 30 diagnosed cases of end stage renal disease (ESRD) attending BPKIHS were included in the study. Group 1 included 10 patients on regular maintenance hemodialysis, group 2 included 10 patients on continuous ambulatory peritoneal dialysis (CAPD) and group 3 included 10 patients on regular conservative drugs. The inclusion criteria were all diagnosed cases of ESRD based on the guidelines given by K/DOQI, 2002. A detailed history relating to the disease condition as per the designed proforma was taken, which included demographic data and clinical characteristics of the patients. For assessment of quality of life, KDQOL-SF questionnaire was used. Strata 8.0 software program was used for the analysis of collected data. Physical health was found to be the most severely affected domain of the KDQOL. The mean score for physical health was least in group 1 (33.36 +/- 16.14). Mental health was better in group 2 (54.93 +/- 9.92) than in group 1 (39.50 +/- 14.27) ( "p" value 0.01). Variables like haemoglobin, hematocrit and adequacy of dialysis have positive correlation with all the four domains of the KDQOL. There was a statistically significant correlation of physical health with mental health (p value 0.001), physical health with kidney disease issues (p value 0.001) and mental health with kidney disease issues (p value 0.007). Our study has shown that patients of ESRD have a poor quality of life despite being in some form of dialysis and the most affected domain of the KDQOL scale is physical health. Patients on CAPD have better quality of life than patients on maintenance haemodialysis especially in terms of mental health. Variables like haemoglobin, hematocrit and adequacy of dialysis have a positive correlation with all the four domains of the KDQOL scale i.e. optimizing these variables improves the overall quality of life.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to amyloid-beta (Aβ) protofibrils, was formally evaluated as a treatment for early Alzheimer's disease in a phase 2 study (Study 201) and the phase 3 Clarity AD study. These trials both included an 18-month, randomized study (core) and an open-label extension (OLE) phase where eligible participants received open-label lecanemab for up to 30 months to date. Clinical (CDR-SB, ADAS-Cog14, and ADCS-MCI-ADL), biomarker (PET, Aβ42/40 ratio, and ptau181) and safety outcomes were evaluated.
View Article and Find Full Text PDFAlzheimer's disease pathophysiology is believed to involve various abnormalities, including those of amyloid beta (Ab) peptide and tau processing, inflammation, oxidative stress, and vascular risk factors. Aβ peptides exist in a dynamic continuum of conformational states from monomeric Aβ, to soluble progressively larger Aβ assemblies that include a range of low molecular weight oligomers to higher molecular weight protofibrils, and finally to insoluble fibrils (plaques). Various lines of evidence support the "amyloid hypothesis" that Aβ plays a central role in the pathogenesis of AD, and several immunotherapies have been developed to interact with this cascade in various different places which may reduce the number of soluble aggregates and insoluble Aβ fibrils deposited in the brain.
View Article and Find Full Text PDFBackground: Lecanemab is an approved anti-amyloid monoclonal antibody that binds with highest affinity to soluble Aβ protofibrils, which are more toxic than monomers or insoluble fibrils/plaque. In clinical studies, biweekly lecanemab treatment demonstrated a slowing of decline in clinical (global, cognitive, functional, and quality of life) outcomes, and reduction in brain amyloid in early Alzheimer's disease (AD). Herein, we describe the impact of lecanemab treatment on tau PET.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Stevenson University, Owings Mills, MD, USA.
Background: Most assisted living (AL) settings organize and provide opportunities for residents to participate in activities (e.g., exercise, music, arts and craft, cognitive activities, religious services, community outings).
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!